Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review

Por Ormel, H.L., van der Schoot, G.G.F., Sluiter, W.J., Jalving, M., Gietema, J.A., Walenkamp, A.M.E.
Publicado no Psychooncology (2018)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity

Por Gooden, M J M, Wiersma, V R, Boerma, A, Leffers, N, Boezen, H M, ten Hoor, K A, Hollema, H, Walenkamp, A M E, Daemen, T, Nijman, H W, Bremer, E
Publicado em 2014

TGF-β is an inducer of ZEB1-dependent mesenchymal transdifferentiation in glioblastoma that is associated with tumor invasion

Por Joseph, J V, Conroy, S, Tomar, T, Eggens-Meijer, E, Bhat, K, Copray, S, Walenkamp, A M E, Boddeke, E, Balasubramanyian, V, Wagemakers, M, den Dunnen, W F A, Kruyt, F A E
Publicado no Cell Death Dis (2014)

P08.71 Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis

Por van Linde, M. E., Brahm, C. G., de Witt Hamer, P. C., Reijneveld, J. C., Bruynzeel, A. M., Wagemakers, M., van der Weide, H. L., Enting, R. H., Verheul, H. M. W., Walenkamp, A. M. E.
Publicado no Neuro Oncol (2016)

Microenvironment involved in FPR1 expression by human glioblastomas

Por Boer, J. C., van Marion, D. M. S., Joseph, J. V., Kliphuis, N. M., Timmer-Bosscha, H., van Strijp, J. A. G., de Vries, E. G. E., den Dunnen, W. F. A., Kruyt, F. A. E., Walenkamp, A. M. E.
Publicado no J Neurooncol (2015)

IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB

Por French, Pim, Erdem-Eraslan, L., Kros, J.M., Oosterkamp, H.M., Walenkamp, A.M.E., Beerepoot, L., Hanse, M., Buter, J., Honkoop, A., van der Holt, B., Vernhout, R.M., Sillevis Smitt, P.A.E., Taal, W., van den Bent, M.J.
Publicado em 2014

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomusti...

Por Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, H M, Walenkamp, A M, Beerepoot, L, Hanse, M, van Linde, M E, Otten, A, Vernhout, R M, de Vos, F Y F, Gratama, J W, Sleijfer, S, van den Bent, M J
Publicado no Br J Cancer (2015)

Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis Inhibitory Protein of S. aureus

Por Boer, J C, Domanska, U M, Timmer-Bosscha, H, Boer, I G J, de Haas, C J C, Joseph, J V, Kruyt, F A E, de Vries, E G E, den Dunnen, W F A, van Strijp, J A G, Walenkamp, A M E
Publicado em 2013

O10.05 FINAL ANALYSIS OF THE BELOB TRIAL (A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENT IN RECURRENT GLIOBLASTOMA) AND...

Por Taal, W., Oosterkamp, H.M., Walenkamp, A.M.E., Dubbink, H.J., Beerepoot, L.V., Hanse, M., Buter, J., Honkoop, A., Boerman, D., Vos, F.Y.F., Dinjens, W.N.M., Enting, R.H., Taphoorn, M.J.B., van den Berkmortel, F.W.P.J., Jansen, R., Brandsma, D., Bromberg, J.E., van Heuvel, I., Vernhout, R.M., van der Holt, B., van den Bent, M.J.
Publicado em 2014